Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study

Abstract

Abstract Background Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum‐based induction in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment during early or late NSCLC have not yet been characterized. Methods We retrospectively analyzed data from 35 patients with advanced naïve NSCLC who had received pemetrexed/platinum with or without bevacizumab followed by maintenance therapy with pemetrexed alone or pemetrexed plus bevacizumab. The data were analyzed using the Kaplan‐Meier method and Cox regression adjusted for risk factors. Patients were grouped according to treatment conditions. Group A received pemetrexed plus platinum followed by pemetrexed alone (Pem‐Pt/Pem). Group B received pemetrexed plus platinum followed by pemetrexed and bevacizumab (Group B; Pem‐Pt/Pem + Bev). Group C received pemetrexed, platinum, and bevacizumab during induction therapy, and pemetrexed as maintenance therapy (Group C; Pem‐Pt + Bev/Pem + Bev). We assessed the significance of introduction of bevacizumab at different stages of treatment. Results A total of 13 (37.1%) patients were included in Group A, nine patients (25.7%) were included in Group B, and 13 patients (37.1%) were included in Group C. Among the 35 patients, 69.2% were male, and the median age was 59 years (range 40–75). The median progression‐free survival (PFS) was 7.7 months (231 days, range 134–410 days) in Group A, 9.3 months (280 days, range 84–565 days) in Group B, and 8.0 months (241 days, range 108–665 days) in Group C. The median PFS was not significantly different among the three groups (P = 0.233). Similarly, bevacizumab did not significantly affect PFS (P = 0.630). Conclusions The addition of bevacizumab into induction chemotherapy or maintenance therapy provided limited benefits to PFS in our study, but previous studies suggested that bevacizumab may improve disease control. In that way, we presume that early use of bevacizumab may provide a greater benefit.

Keywords

• Antiangiogenic targeted therapy
• chemotherapy
• pemetrexed
• progressive‐free survival